Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | PPID | Q08752 | 4/20 | 0.50 |
| ▸ | PPIB | P23284 | 2/20 | 0.50 |
| ▸ | PPIA | P62937 | 1/20 | 0.50 |
| ▸ | PPIG | Q13427 | 1/20 | 0.50 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15939528 | 0.84 | PPID (0.65) | EPHX2EPHX1PPIDPPIBPPIA | |
| SCHEMBL258716 | 0.84 | CYP2C9 (0.62) | EPHX2EPHX1PPIDPPIBPPIA | |
| SCHEMBL8245710 | 0.83 | CYP2C9 (0.68) | EPHX2EPHX1PPIDPPIBPPIA | |
| Hydrochloric Acid SCHEMBL7441659 | 0.83 | CYP2C9 (0.60) | EPHX2EPHX1PPIDPPIBPPIA | |
| SCHEMBL1800569 | 0.81 | KMT2A (0.63) | EPHX2EPHX1PPIDPPIBPPIA | |
| SCHEMBL13342380 | 0.81 | EPHX2 (0.51) | EPHX2EPHX1PPIDPPIBPPIA | |
| SCHEMBL12643752 | 0.81 | EPHX1 (0.58) | EPHX2EPHX1PPIDPPIBPPIA | |
| SCHEMBL22060071 | 0.80 | ERCC1 (0.60) | EPHX2EPHX1PPIDPPIBPPIA | |
| SCHEMBL8573694 | 0.80 | EPHX2 (0.47) | EPHX2EPHX1PPIDPPIBPPIA | |
| SCHEMBL21781874 | 0.79 | CA1 (0.64) | EPHX2EPHX1PPIDPPIBPPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210023094-A1 | PSMA ANTIBODY-DRUG CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2021-01-28 | — | — | US | claimed |
| EP-2727606-A2 | Compounds for killing psma-expressing, taxane-resistant cancer cells | Psma Development Company, L.L.C. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-1912677-B1 | PSMA antibody-drug conjugates | PSMA DEV COMPANY L L C (US) | 2013-10-02 | — | — | EP | claimed |
| EP-2326350-B1 | COMPOUNDS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | PSMA DEV COMPANY L L C (US) | 2013-09-04 | — | — | EP | claimed |
| EP-2326350-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | Psma Development Company, L.L.C. (US) | 2011-06-01 | — | — | EP | claimed |
| WO-2010027513-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | PSMA DEVELOPMENT COMPANY, LLC (US) | 2010-03-11 | — | — | WO | claimed |
| US-6214345-B1 | ANTITUMOR AGENTS; DRUG CONJUGATES WHICH ARE SELECTIVELY ACTIVATIBLE AT THE SITE OF THE TUMOR | BRISTOL-MYERS SQUIBB CO. | 2001-04-10 | — | — | US | claimed |
| EP-3827844-A1 | COMBINATION THERAPIES WITH PSMA LIGAND CONJUGATES | Psma Development Company, L.L.C. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20210023094-A1 | PSMA ANTIBODY-DRUG CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2021-01-28 | — | — | US | disclosed |
| EP-3057614-B1 | COMBINATION THERAPIES WITH PSMA LIGAND CONJUGATES | PSMA DEV COMPANY L L C (US) | 2020-09-30 | — | — | EP | disclosed |
| US-9242012-B2 | Methods for killing PSMA-expressing, taxane-resistant cancer cells | PSMA DEVELOPMENT COMPANY, LLC (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150110814-A1 | COMBINATION THERAPIES WITH PSMA LIGAND CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2015-04-23 | — | — | US | disclosed |
| EP-2727606-A2 | Compounds for killing psma-expressing, taxane-resistant cancer cells | Psma Development Company, L.L.C. (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-1912677-B1 | PSMA antibody-drug conjugates | PSMA DEV COMPANY L L C (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2326350-B1 | COMPOUNDS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | PSMA DEV COMPANY L L C (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20110250216-A1 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | PSMA DEVELOPMENT COMPANY, LLC (US) | 2011-10-13 | — | — | US | disclosed |
| EP-2326350-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | Psma Development Company, L.L.C. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010027513-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | PSMA DEVELOPMENT COMPANY, LLC (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20070160617-A1 | PSMA antibody-drug conjugates | PSMA DEVELOPMENT COMPANY, LLC (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150110814-A1 | COMBINATION THERAPIES WITH PSMA LIGAND CONJUGATES | CD47, CD4, PSMA1 | EPHX2 2283/4885EPHX1 1753/4885PPID 3023/4885 |
| US-20210023094-A1 | PSMA ANTIBODY-DRUG CONJUGATES | FOLH1, PSMA3, PSMA2 | EPHX2 517/4885EPHX1 2265/4885PPID 3347/4885 |
| US-20110250216-A1 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | FOLH1, DNPEP, KLK3 | EPHX2 2534/4885EPHX1 2788/4885PPID 3023/4885 |
| US-20070160617-A1 | PSMA antibody-drug conjugates | FOLH1, PSMA3, PSMA2 | EPHX2 517/4885EPHX1 2265/4885PPID 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.